Search clinical trials for: PD-1 antibody injection

Total 1724 results

Nanjing Leads Biolabs Co.,Ltd

Recruiting

Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors

Advanced Malignant Tumors

China
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)

Alveolar Soft Part Sarcoma

China
Shanghai Henlius Biotech

Recruiting

A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer

Gastric Cancer

China
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

Peripheral T Cell Lymphoma

China
Adagene (Suzhou) Limited

Terminated

Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma

Solid Tumor | Non Hodgkin Lymphoma

China
Genor Biopharma Co., Ltd.
Hutchison Medipharma Limited

Unknown

Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Second Affiliated Hospital, School of Medicine,...
Westlake Therapeutics

Recruiting

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

Advanced Lung Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors

Advanced Solid Tumors
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.

Unknown

JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer

Colorectal Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma

Lymphoma | Tumor, Solid

China
Fudan University
Shanxi Province Cancer Hospital; Inner Mongolia Cancer Hospital Affiliated...

Recruiting

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Advanced Thyroid Cancer Patients Who Received Target Therapy

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

Cholangiocarcinoma

China
Beijing Tongren Hospital

Not yet recruiting

Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma

Extranodal NK/T-cell Lymphoma, Nasal Type
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern... and other collaborators

Recruiting

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Surgery | PD-1

China
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Completed

Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC

Esophageal Cancer

China
Bio-Thera Solutions

Terminated

Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients

Advanced Solid Tumor

Australia
Eye & ENT Hospital of Fudan University

Not yet recruiting

Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Henlix, Inc

Unknown

Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors

Solid Tumor

Taiwan
Bio-Thera Solutions

Terminated

Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients

Advanced Solid Tumour

Australia
Sun Yat-sen University

Recruiting

Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer

Colorectal Cancer Metastatic | MSS

China
Second Affiliated Hospital of Soochow University
SciClone Pharmaceuticals

Recruiting

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Advanced Solid Tumor | Refractory Tumor

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Unknown

Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Zhujiang Hospital

Not yet recruiting

Efficacy and Safety of Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC: A Retrospective Real-world Study

Hepatocellular Carcinoma Non-resectable
Shandong New Time Pharmaceutical Co., LTD

Completed

A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma

Cervical Cancer

China
Shandong New Time Pharmaceutical Co., LTD

Unknown

Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520

Advanced Solid Tumor，Recurrent Solid Tumor，Lymphoma，Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma

China
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx

Solid Tumor

United States
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer
Fudan University

Active, not recruiting

Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer

Thyroid Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer

Uterine Cervical Cancer

China
Cancer Hospital of Guangxi Medical University

Recruiting

Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Sintilimab

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours

Lymphoma | Cervical Cancer | Malignant Mesothelioma | Advanced Solid Tumours | Non-Small-Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Locally Advanced Gastric Adenocarcinoma

China
Pfizer

Withdrawn

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer

Poland, United States
Shanghai Henlius Biotech

Not yet recruiting

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors

Solid Tumor, Adult
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma

Sarcoma, Soft Tissue

China
Chinese PLA General Hospital

Unknown

A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas

Lymphoma | Solid Tumor

China
Guangzhou Gloria Biosciences Co., Ltd.

Completed

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Chongqing University Cancer Hospital

Recruiting

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Nasopharyngeal Carcinoma

China
Hunan Cancer Hospital

Recruiting

Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

Chemotherapy Effect | NK/T-cell Lymphoma of Nasal Cavity | Immune Checkpoint Inhibitor | Epigenetic Disorder

China
Peking University Cancer Hospital & Institute

Recruiting

Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma

Melanoma

China
Peking University Cancer Hospital & Institute

Active, not recruiting

Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma

Melanoma

China
Livzon Pharmaceutical Group Inc.

Completed

LZM009 to Treat Patients With Advanced Solid Tumors

Solid Tumor

United States
Bio-Thera Solutions

Recruiting

Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients

Advanced Solid Tumor

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy (HN)

Head and Neck Cancer

China
Waterstone Hanxbio Pty Ltd

Recruiting

Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma

Relapsed/Refractory Lymphoma

China
Northwestern University
National Cancer Institute (NCI)

Recruiting

Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer

Locally Advanced Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Oncocytic Carcinoma

United States
Navy General Hospital, Beijing

Recruiting

Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

Refractory Classic Hodgkin Lymphoma | Relapsed Classic Hodgkin Lymphoma

China
The Affiliated Hospital of Xuzhou Medical University

Not yet recruiting

Study on the Treatment of Advanced Malignant Solid Tumor With Revottack and PD-1 Inhibitor

Advanced Solid Tumor

China
Sun Yat-sen University
Guangdong Provincial Hospital of Traditional Chinese Medicine; Fujian Cancer... and other collaborators

Recruiting

PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients

Lynch Syndrome

China
RenJi Hospital

Completed

Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma

Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma

China

Search clinical trials for: PD-1 antibody injection

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations